About this Journal Submit a Manuscript Table of Contents
Arthritis
Volume 2012 (2012), Article ID 371909, 17 pages
http://dx.doi.org/10.1155/2012/371909
Review Article

Cardiovascular Disease in Rheumatoid Arthritis: A Systematic Literature Review in Latin America

Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, 111221 Bogotá, Colombia

Received 31 July 2012; Accepted 27 August 2012

Academic Editor: Claudio Galarza-Maldonado

Copyright © 2012 Juan Camilo Sarmiento-Monroy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. L. Scott, F. Wolfe, and T. W. J. Huizinga, “Rheumatoid arthritis,” The Lancet, vol. 376, no. 9746, pp. 1094–1108, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. A. N. DeMaria, “Relative risk of cardiovascular events in patients with rheumatoid arthritis,” American Journal of Cardiology, vol. 89, no. 6, pp. 33D–38D, 2002. View at Scopus
  3. A. Sandoo, J. J. C. S. Veldhuijzen van Zanten, G. S. Metsios, D. Carroll, and G. D. Kitas, “Vascular function and morphology in rheumatoid arthritis: a systematic review,” Rheumatology, vol. 50, pp. 2125–2139, 2011.
  4. P. Sarzi-Puttini, F. Atzeni, R. Gerli et al., “Cardiac involvement in systemic rheumatic diseases: an update,” Autoimmunity Reviews, vol. 9, no. 12, pp. 849–852, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Farzaneh-Far and M. J. Roman, “Accelerated atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus,” International Journal of Clinical Practice, vol. 59, no. 7, pp. 823–824, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. H. R. Kramer and J. T. Giles, “Cardiovascular disease risk in rheumatoid arthritis: progress, debate, and opportunity,” Arthritis Care & Research, vol. 63, no. 4, pp. 484–499, 2011. View at Scopus
  7. E. Myasoedova and S. E. Gabriel, “Cardiovascular disease in rheumatoid arthritis: a step forward,” Current Opinion in Rheumatology, vol. 22, no. 3, pp. 342–347, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Sattar and I. B. McInnes, “Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions,” Current Opinion in Rheumatology, vol. 17, no. 3, pp. 286–292, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. S. M. A. Toloza, A. G. Uribe, G. McGwin et al., “Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIII. Baseline predictors of vascular events,” Arthritis and Rheumatism, vol. 50, no. 12, pp. 3947–3957, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Sherer and Y. Shoenfeld, “Antiphospholipid syndrome, antiphospholipid antibodies, and atherosclerosis,” Current Atherosclerosis Reports, vol. 3, no. 4, pp. 328–333, 2001. View at Scopus
  11. K. Veres, G. Lakos, A. Kerényi et al., “Antiphospholipid antibodies in acute coronary syndrome,” Lupus, vol. 13, no. 6, pp. 423–427, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Cervera, “Coronary and valvular syndromes and antiphospholipid antibodies,” Thrombosis Research, vol. 114, no. 5-6, pp. 501–507, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Guiducci, R. Giacomelli, and M. M. Cerinic, “Vascular complications of scleroderma,” Autoimmunity Reviews, vol. 6, no. 8, pp. 520–523, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Pérez-De-Lis, M. Akasbi, A. Sisö et al., “Cardiovascular risk factors in primary Sögren's syndrome: a case-control study in 624 patients,” Lupus, vol. 19, no. 8, pp. 941–948, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Stavropoulos-Kalinoglou, G. S. Metsios, V. F. Panoulas et al., “Associations of obesity with modifiable risk factors for the development of cardiovascular disease in patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 68, no. 2, pp. 242–245, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. V. F. Panoulas, G. S. Metsios, A. V. Pace et al., “Hypertension in rheumatoid arthritis,” Rheumatology, vol. 47, no. 9, pp. 1286–1298, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. R. M. R. Pereira, J. F. de Carvalho, and E. Bonfá, “Metabolic syndrome in rheumatological diseases,” Autoimmunity Reviews, vol. 8, no. 5, pp. 415–419, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. V. F. Panoulas, K. M. J. Douglas, H. J. Milionis et al., “Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis,” Rheumatology, vol. 46, no. 9, pp. 1477–1482, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. M. J. Kaplan, “Cardiovascular disease in rheumatoid arthritis,” Current Opinion in Rheumatology, vol. 18, no. 3, pp. 289–297, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. G. D. Kitas and S. E. Gabriel, “Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives,” Annals of the Rheumatic Diseases, vol. 70, pp. 8–14, 2011. View at Publisher · View at Google Scholar
  21. N. J. Goodson, N. J. Wiles, M. Lunt, E. M. Barrett, A. J. Silman, and D. P. M. Symmons, “Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients,” Arthritis and Rheumatism, vol. 46, no. 8, pp. 2010–2019, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Sattar, D. W. McCarey, H. Capell, and I. B. McInnes, “Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis,” Circulation, vol. 108, no. 24, pp. 2957–2963, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. S. L. Whittle and R. A. Hughes, “Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review,” Rheumatology, vol. 43, no. 3, pp. 267–271, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. S. H. Kim, C. K. Lee, Y. L. Eun et al., “Serum oxidized low-density lipoproteins in rheumatoid arthritis,” Rheumatology International, vol. 24, no. 4, pp. 230–233, 2004. View at Scopus
  25. A. Rojas-Villarraga, O. D. Ortega-Hernandez, L. F. Gomez et al., “Risk factors associated with different stages of atherosclerosis in colombian patients with rheumatoid arthritis,” Seminars in Arthritis and Rheumatism, vol. 38, no. 2, pp. 71–82, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Levendoglu, A. Temizhan, H. Ugurlu, A. Ozdemir, and M. Yazici, “Ventricular function abnormalities in active rheumatoid arthritis: a Doppler echocardiographic study,” Rheumatology International, vol. 24, no. 3, pp. 141–146, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Gonzalez-Juanatey, A. Testa, A. Garcia-Castelo et al., “Echocardiographic and doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease,” Seminars in Arthritis and Rheumatism, vol. 33, no. 4, pp. 231–238, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. A. E. Voskuyl, “The heart and cardiovascular manifestations in rheumatoid arthritis,” Rheumatology, vol. 45, supplement 4, pp. iv4–iv7, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. V. R. da Cunha, C. V. Brenol, J. C. T. Brenol, and R. M. Xavier, “Rheumatoid arthritis and metabolic syndrome,” Revista Brasileira de Reumatologia, vol. 51, no. 3, pp. 260–268, 2011. View at Scopus
  30. M. Cisternas, M. A. Gutiérrez, J. Klaassen, A. M. Acosta, and S. Jacobelli, “Cardiovascular risk factors in Chilean patients with rheumatoid arthritis,” Journal of Rheumatology, vol. 29, no. 8, pp. 1619–1622, 2002. View at Scopus
  31. D. H. Solomon, E. W. Karlson, E. B. Rimm et al., “Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis,” Circulation, vol. 107, no. 9, pp. 1303–1307, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Chan, Global Status Report on Noncommunicable Diseases, World Health Organization, 2010.
  33. D. Yach, C. Hawkes, C. L. Gould, and K. J. Hofman, “The global burden of chronic diseases: overcoming impediments to prevention and control,” Journal of the American Medical Association, vol. 291, no. 21, pp. 2616–2622, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. A. L. Price, N. Patterson, F. Yu et al., “A genomewide admixture map for latino populations,” American Journal of Human Genetics, vol. 80, no. 6, pp. 1024–1036, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Yazici, H. Kautiainen, and T. Sokka, “Differences in clinical status measures in different ethnic/racial groups with early rheumatoid arthritis: implications for interpretation of clinical trial data,” Journal of Rheumatology, vol. 34, no. 2, pp. 311–315, 2007. View at Scopus
  36. B. Bruce, J. F. Fries, and K. N. Murtagh, “Health status disparities in ethnic minority patients with rheumatoid arthritis: a cross-sectional study,” Journal of Rheumatology, vol. 34, no. 7, pp. 1475–1479, 2007. View at Scopus
  37. Y. Shoenfeld, R. Gerli, A. Doria et al., “Accelerated atherosclerosis in autoimmune rheumatic diseases,” Circulation, vol. 112, no. 21, pp. 3337–3347, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. I. Avalos, Y. H. Rho, C. P. Chung, and C. M. Stein, “Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus,” Clinical and Experimental Rheumatology, vol. 26, no. 5, pp. S5–S13, 2008. View at Scopus
  39. L. E. Full, C. Ruisanchez, and C. Monaco, “The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus,” Arthritis Research & Therapy, vol. 11, no. 2, p. 217, 2009. View at Scopus
  40. L. Massardo, B. A. Pons-Estel, D. Wojdyla, M. H. Cardiel, C. M. Galarza-Maldonado, M. P. Sacnun, et al., “Early rheumatoid arthritis in Latin America: low socioeconomic status related to high disease activity at baseline,” Arthritis Care & Research, vol. 64, pp. 1135–1143, 2012.
  41. A. Spindler, V. Bellomio, A. Berman et al., “Prevalence of rheumatoid arthritis in Tucumán, Argentina,” Journal of Rheumatology, vol. 29, no. 6, pp. 1166–1170, 2002. View at Scopus
  42. I. Peláez-Ballestas, L. H. Sanin, J. Moreno-Montoya et al., “Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology,” Journal of Rheumatology, supplement, vol. 86, pp. 3–6, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. J. M. Anaya, P. A. Correa, R. D. Mantilla, F. Jimenez, T. Kuffner, and J. M. McNicholl, “Rheumatoid arthritis in African Colombians from Quibdo,” Seminars in Arthritis and Rheumatism, vol. 31, no. 3, pp. 191–198, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Liberati, D. G. Altman, J. Tetzlaff, C. Mulrow, P. C. Gøtzsche, J. P. A. Ioannidis, et al., “The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration,” Journal of Clinical Epidemiology, vol. 62, pp. e1–34, 2009.
  45. OCEBM Levels of Evidence Working Group, “The Oxford 2011 Levels of Evidence,” Oxford Centre for Evidence-Based Medicine, 2011.
  46. J. Orozco-Alcalá, T. Gómez-Ocegueda, and L. Garcia-Benavides, “Causas de muerte en pacientes con artritis reumatoide del adulto,” Revista Mexicana de Reumatología, vol. 8, pp. 195–201, 1993.
  47. N. E. Zavaleta, E. Alexánderson, M. E. Soto, M. Flores, and M. C. Amigo, “Analysis of the ulsefulnes of contrast echocardiography and nuclear medicine in cardiovascular affection due to autoimmune diseases,” Archivos de Cardiologia de Mexico, vol. 75, no. 1, pp. 42–48, 2005. View at Scopus
  48. M. A. Lopez-Olivo, L. Gonzalez-Lopez, A. Garcia-Gonzalez et al., “Factors associated with hyperhomocysteinaemia in Mexican patients with rheumatoid arthritis,” Scandinavian Journal of Rheumatology, vol. 35, no. 2, pp. 112–116, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Daza, M. Aguirre, M. Jimenez, R. Herrera, and J. J. Bollain, “Common carotid intima-media thickness and von Willebrand factor serum levels in rheumatoid arthritis female patients without cardiovascular risk factors,” Clinical Rheumatology, vol. 26, no. 4, pp. 533–537, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Zonana-Nacach, E. Santana-Sahagún, F. J. Jiménez-Balderas, and A. Camargo-Coronel, “Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus,” Journal of Clinical Rheumatology, vol. 14, no. 2, pp. 74–77, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. I. Pereira, I. Laurindo, R. Burlingame et al., “Auto-antibodies do not influence development of atherosclerotic plaques in rheumatoid arthritis,” Joint Bone Spine, vol. 75, no. 4, pp. 416–421, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. I. A. Pereira, I. M. M. Laurindo, A. F. Zimmermann, G. R. W. Castro, F. Mello, and E. F. Borba, “Single measurements of C-reactive protein and disease activity scores are not predictors of carotid at herosclerosis in rheumatoid arthritis patients,” Acta Reumatologica Portuguesa, vol. 34, no. 1, pp. 58–64, 2009. View at Scopus
  53. V. da Cunha, C. Brenol, J. Brenol, S. Fuchs, E. Arlindo, I. Melo, et al., “Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity,” Scandinavian Journal of Rheumatology, vol. 41, pp. 186–191, 2012. View at Publisher · View at Google Scholar
  54. R. Pineda, G. Arcila, P. Restrepo, and J. M. Anaya, “Impacto de la enfermedad cardiovascular en los costos de hospitalización de pacientes con artritis reumatoidea,” Biomédica, vol. 24, pp. 366–374, 2004.
  55. O. D. Ortega-Hernandez, R. Pineda-Tamayo, A. L. Pardo, A. Rojas-Villarraga, and J. M. Anaya, “Cardiovascular disease is associated with extra-articular manifestations in patients with rheumatoid arthritis,” Clinical Rheumatology, vol. 28, no. 7, pp. 767–775, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Larroude and A. Romanowicz, “Artritis Reumatoidea y aterosclerosis,” Revista Argentina de Reumatología, vol. 14, pp. 16–24, 2003.
  57. C. Lascano, P. Alba, C. Gobbi, F. Videla, F. Campos, H. Sosa, et al., “Disfunción diastólica ventricular izquierda en la artritis reumatoidea,” Revista de la Facultad de Ciencias Médicas, vol. 66, pp. 58–65, 2009.
  58. R. R. Acosta, C. Castell, M. Hernandez, and A. Pernas, “Comorbilidad y mortalidad en una cohorte de pacientes cubanos con artritis reumatoide,” Revista Cubana de Medicina, vol. 48, pp. 1–12, 2009.
  59. Y. Santiago-Casas, T. C. González-Rivera, L. E. Castro-Santana et al., “Impact of age on clinical manifestations and outcome in Puerto Ricans with rheumatoid arthritis,” Ethnicity & Disease, vol. 20, supplement 1, pp. S1–S191, 2010. View at Scopus
  60. A. Barceló, “Cardiovascular diseases in Latin America and the Caribbean,” The Lancet, vol. 368, no. 9536, pp. 625–626, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Schargrodsky, R. Hernández-Hernández, B. M. Champagne et al., “CARMELA: assessment of cardiovascular risk in seven latin American cities,” American Journal of Medicine, vol. 121, no. 1, pp. 58–65, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. B. Indicators, “Basic Indicators 2011,” 2011.
  63. A. M. Delgado-Vega and J. M. Anaya, “Meta-analysis of HLA-DRB1 polymorphism in Latin American patients with rheumatoid arthritis,” Autoimmunity Reviews, vol. 6, no. 6, pp. 402–408, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. A. Delgado-Vega, J. Martín, J. Granados, and J. M. Anaya, “Epidemiología genética de la artritis reumatoide: qué esperar de América Latina?” Biomédica, vol. 26, no. 4, pp. 562–584, 2006.
  65. X. Mao, A. W. Bigham, R. Mei et al., “A genomewide admixture mapping panel for hispanic/latino populations,” American Journal of Human Genetics, vol. 80, no. 6, pp. 1171–1178, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. J. A. Aviña-Zubieta, H. K. Choi, M. Sadatsafavi, M. Etminan, J. M. Esdaile, and D. Lacaille, “Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies,” Arthritis Care and Research, vol. 59, no. 12, pp. 1690–1697, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Lindhardsen, O. Ahlehoff, G. H. Gislason, O. R. Madsen, J. B. Olesen, J. H. Svendsen, et al., “Risk of atrial fibrillation and stroke in rheumatoid arthritis: danish nationwide cohort study,” British Medical Journal, vol. 344, article, 2012.
  68. S. A. Karvounaris, P. I. Sidiropoulos, J. A. Papadakis et al., “Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study,” Annals of the Rheumatic Diseases, vol. 66, no. 1, pp. 28–33, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. E. Gremese and G. Ferraccioli, “The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk,” Autoimmunity Reviews, vol. 10, pp. 582–589, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. T. E. Toms, V. F. Panoulas, and G. D. Kitas, “Dyslipidaemia in rheumatological autoimmune diseases,” The Open Cardiovascular Medicine Journal, vol. 5, pp. 64–75, 2011. View at Publisher · View at Google Scholar
  71. C. P. Chung, A. Oeser, J. F. Solus et al., “Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis,” Atherosclerosis, vol. 196, no. 2, pp. 756–763, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Van Doornum, G. McColl, and I. P. Wicks, “Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?” Arthritis and Rheumatism, vol. 46, no. 4, pp. 862–873, 2002. View at Publisher · View at Google Scholar · View at Scopus
  73. M. A. Gonzalez-Gay, C. Gonzalez-Juanatey, M. J. Lopez-Diaz et al., “HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis,” Arthritis Care and Research, vol. 57, no. 1, pp. 125–132, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. M. A. Gonzalez-Gay, C. Gonzalez-Juanatey, and W. E. Ollier, “Endothelial dysfunction in rheumatoid arthritis: influence of HLA-DRB1 alleles,” Autoimmunity Reviews, vol. 3, no. 4, pp. 301–304, 2004. View at Publisher · View at Google Scholar · View at Scopus
  75. T. M. Farragher, N. J. Goodson, H. Naseem et al., “Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis,” Arthritis and Rheumatism, vol. 58, no. 2, pp. 359–369, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. C. Turesson, R. L. McClelland, T. J. H. Christianson, and E. L. Matteson, “Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 66, no. 1, pp. 70–75, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. C. Turesson, W. M. O'Fallon, C. S. Crowson, S. E. Gabriel, and E. L. Matteson, “Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis,” Journal of Rheumatology, vol. 29, no. 1, pp. 62–67, 2002. View at Scopus
  78. P. Soltész, G. Kerekes, H. Dér et al., “Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment,” Autoimmunity Reviews, vol. 10, no. 7, pp. 416–425, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. C. Gonzalez-Juanatey, A. Testa, A. Garcia-Castelo et al., “HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis,” American Journal of Medicine, vol. 114, no. 8, pp. 647–652, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. C. Gonzalez-Juanatey, J. Llorca, J. Martin, and M. A. Gonzalez-Gay, “Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis,” Seminars in Arthritis and Rheumatism, vol. 38, no. 5, pp. 366–371, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. V. F. Panoulas, K. M. J. Douglas, J. P. Smith et al., “Polymorphisms of the endothelin-1 gene associate with hypertension in patients with rheumatoid arthritis,” Endothelium, vol. 15, no. 4, pp. 203–212, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. R. Palomino-Morales, C. Gonzalez-Juanatey, T. R. Vazquez-Rodriguez et al., “A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis,” Arthritis Research and Therapy, vol. 12, no. 2, article R71, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. L. Rodríguez-Rodríguez, C. González-Juanatey, R. Palomino-Morales et al., “TNFA -308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis,” Atherosclerosis, vol. 216, no. 1, pp. 125–130, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. R. López-Mejías, M. García-Bermúdez, C. González-Juanatey, S. Castañeda, J. A. Miranda-Filloy, C. Gómez-Vaquero, et al., “NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis,” Atherosclerosis, vol. 224, no. 2, pp. 426–429, 2012.
  85. L. Rodríguez-Rodríguez, C. González-Juanatey, M. García-Bermúdez, T. R. Vázquez-Rodríguez, J. A. Miranda-Filloy, B. Fernández-Gutiérrez, et al., “CCR5Δ32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort study,” Arthritis Research & Therapy, vol. 13, article R133, 2011.
  86. M. Heliovaara, K. Aho, P. Knekt, A. Aromaa, J. Maatela, and A. Reunanen, “Rheumatoid factor, chronic arthritis and mortality,” Annals of the Rheumatic Diseases, vol. 54, no. 10, pp. 811–814, 1995. View at Scopus
  87. S. H. Kim, C. K. Lee, Y. L. Eun et al., “Serum oxidized low-density lipoproteins in rheumatoid arthritis,” Rheumatology International, vol. 24, no. 4, pp. 230–233, 2004. View at Scopus
  88. A. M. B. Medeiros, C. A. Von Mühlen, M. A. Gidlund, R. Bodanese, M. G. V. Gottlieb, and L. C. Bodanese, “Antibodies against oxLDL and acute coronary syndrome,” Arquivos Brasileiros de Cardiologia, vol. 95, no. 1, pp. 47–54, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. M. H. Snow and T. R. Mikuls, “Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention,” Current Opinion in Rheumatology, vol. 17, no. 3, pp. 234–241, 2005. View at Publisher · View at Google Scholar · View at Scopus
  90. F. Ingegnoli, F. Fantini, E. G. Favalli et al., “Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-α blockade,” Journal of Autoimmunity, vol. 31, no. 2, pp. 175–179, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. B. J. Radovits, D. A. Popa-Diaconu, C. Popa et al., “Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 68, no. 8, pp. 1271–1276, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. H. Maradit-Kremers, P. J. Nicola, C. S. Crowson, K. V. Ballman, and S. E. Gabriel, “Cardiovascular death in rheumatoid arthritis: a population-based study,” Arthritis and Rheumatism, vol. 52, no. 3, pp. 722–732, 2005. View at Publisher · View at Google Scholar · View at Scopus
  93. M. J. L. Peters, D. P. M. Symmons, D. McCarey et al., “EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis,” Annals of the Rheumatic Diseases, vol. 69, no. 2, pp. 325–331, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. V. F. Panoulas, K. M. J. Douglas, A. Stavropoulos-Kalinoglou et al., “Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis,” Rheumatology, vol. 47, no. 1, pp. 72–75, 2008. View at Publisher · View at Google Scholar · View at Scopus
  95. P. H. Dessein, B. I. Joffe, A. E. Stanwix, B. F. Christian, and M. Veller, “Glucocorticoids and insulin sensitivity in rheumatoid arthritis,” Journal of Rheumatology, vol. 31, no. 5, pp. 867–874, 2004. View at Scopus
  96. W. Foster, D. Carruthers, G. Y. H. Lip, and A. D. Blann, “Inflammation and microvascular and macrovascular endothelial dysfunction in rheumatoid arthritis: effect of treatment,” Journal of Rheumatology, vol. 37, no. 4, pp. 711–716, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. A. Södergren, K. Karp, K. Boman et al., “Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness,” Arthritis Research and Therapy, vol. 12, no. 4, article R158, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. K. P. Liao, “Cardiovascular disease in rheumatoid arthritis,” The Rheumatologist, July 2012.